KR100623322B1 - 경구투여용 항말라리아 배합 제제 및 그의 제조방법 - Google Patents
경구투여용 항말라리아 배합 제제 및 그의 제조방법 Download PDFInfo
- Publication number
- KR100623322B1 KR100623322B1 KR1020040088413A KR20040088413A KR100623322B1 KR 100623322 B1 KR100623322 B1 KR 100623322B1 KR 1020040088413 A KR1020040088413 A KR 1020040088413A KR 20040088413 A KR20040088413 A KR 20040088413A KR 100623322 B1 KR100623322 B1 KR 100623322B1
- Authority
- KR
- South Korea
- Prior art keywords
- althesunate
- composition
- salt
- pyrinaridine
- acid
- Prior art date
Links
- 239000003430 antimalarial agent Substances 0.000 title abstract description 11
- 230000000078 anti-malarial effect Effects 0.000 title abstract description 8
- 238000002360 preparation method Methods 0.000 title description 44
- 239000000203 mixture Substances 0.000 claims abstract description 60
- DJUFPMUQJKWIJB-UHFFFAOYSA-N pyronaridine Chemical compound C12=NC(OC)=CC=C2N=C2C=C(Cl)C=CC2=C1NC(C=C(CN1CCCC1)C=1O)=CC=1CN1CCCC1 DJUFPMUQJKWIJB-UHFFFAOYSA-N 0.000 claims abstract description 46
- 229950011262 pyronaridine Drugs 0.000 claims abstract description 46
- 238000009472 formulation Methods 0.000 claims abstract description 31
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 239000003937 drug carrier Substances 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 33
- 239000008187 granular material Substances 0.000 claims description 27
- 239000002202 Polyethylene glycol Substances 0.000 claims description 19
- 229920001223 polyethylene glycol Polymers 0.000 claims description 19
- 201000004792 malaria Diseases 0.000 claims description 18
- 239000003094 microcapsule Substances 0.000 claims description 14
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 239000000374 eutectic mixture Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 2
- 239000008199 coating composition Substances 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- 239000013020 final formulation Substances 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 34
- 229940079593 drug Drugs 0.000 description 29
- 239000003814 drug Substances 0.000 description 29
- 239000004615 ingredient Substances 0.000 description 28
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 27
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 27
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 27
- 230000005496 eutectics Effects 0.000 description 22
- 229960001866 silicon dioxide Drugs 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000000377 silicon dioxide Substances 0.000 description 15
- 235000012239 silicon dioxide Nutrition 0.000 description 15
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 14
- 229960000913 crospovidone Drugs 0.000 description 14
- 235000019359 magnesium stearate Nutrition 0.000 description 14
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 14
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 14
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 13
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 229960003677 chloroquine Drugs 0.000 description 13
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 13
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 11
- 238000007922 dissolution test Methods 0.000 description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 9
- 239000008108 microcrystalline cellulose Substances 0.000 description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- YDHWWBZFRZWVHO-UHFFFAOYSA-H [oxido-[oxido(phosphonatooxy)phosphoryl]oxyphosphoryl] phosphate Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O YDHWWBZFRZWVHO-UHFFFAOYSA-H 0.000 description 8
- 239000000155 melt Substances 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 229920001983 poloxamer Polymers 0.000 description 7
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 6
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 6
- 238000004811 liquid chromatography Methods 0.000 description 6
- 244000045947 parasite Species 0.000 description 6
- 229960000502 poloxamer Drugs 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000223960 Plasmodium falciparum Species 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 239000007902 hard capsule Substances 0.000 description 5
- 229960004838 phosphoric acid Drugs 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000012812 general test Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 4
- 229960000611 pyrimethamine Drugs 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 230000000171 quenching effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 101100119854 Candida albicans FCR3 gene Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 231100000191 repeated dose toxicity Toxicity 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 208000009182 Parasitemia Diseases 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229960004191 artemisinin Drugs 0.000 description 2
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 2
- 229930101531 artemisinin Natural products 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- QMNFFXRFOJIOKZ-UHFFFAOYSA-N cycloguanil Chemical group CC1(C)N=C(N)N=C(N)N1C1=CC=C(Cl)C=C1 QMNFFXRFOJIOKZ-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 235000011078 sorbitan tristearate Nutrition 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- YNWCUCSDUMVJKR-UHFFFAOYSA-N 4-[(7-chloroquinolin-4-yl)amino]-2-(pyrrolidin-1-ylmethyl)phenol Chemical compound OC1=CC=C(NC=2C3=CC=C(Cl)C=C3N=CC=2)C=C1CN1CCCC1 YNWCUCSDUMVJKR-UHFFFAOYSA-N 0.000 description 1
- LUBUTTBEBGYNJN-UHFFFAOYSA-N 4-amino-n-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide;5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1.COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC LUBUTTBEBGYNJN-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000002476 Falciparum Malaria Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010034145 Helminth Proteins Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000224017 Plasmodium berghei Species 0.000 description 1
- 241000224024 Plasmodium chabaudi Species 0.000 description 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 241000223830 Plasmodium yoelii Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 229940009868 aluminum magnesium silicate Drugs 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 229960001444 amodiaquine Drugs 0.000 description 1
- 229950009959 amopyroquine Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229960000981 artemether Drugs 0.000 description 1
- 229960002521 artenimol Drugs 0.000 description 1
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 description 1
- 229960004991 artesunate Drugs 0.000 description 1
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
- 229930016266 dihydroartemisinin Natural products 0.000 description 1
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940047642 disodium cocoamphodiacetate Drugs 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- -1 for example Polymers 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 229910001701 hydrotalcite Inorganic materials 0.000 description 1
- 229960001545 hydrotalcite Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229960001962 mefloquine Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229940089019 pyrimethamine / sulfadoxine Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- JWZSXZWCWMCYPE-RSAXXLAASA-M sodium;(4s)-4-amino-5-dodecoxy-5-oxopentanoate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)[C@@H](N)CCC([O-])=O JWZSXZWCWMCYPE-RSAXXLAASA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940032330 sulfuric acid Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
시험기간 (단위; 주) | 성상 | 함량 시험(90.0-110.0%) | 용출 시험(%) | ||
알테수네이트 | 피로나리딘 | 알테수메이트 (80% 이상) | 피로나리딘 (80% 이상) | ||
0 | 이상없음 | 99.8 | 100.5 | 87.2 | 95.0 |
4 | 이상없음 | 98.5 | 100.1 | 85.8 | 93.5 |
8 | 이상없음 | 98.2 | 99.2 | 86.9 | 95.2 |
12 | 이상없음 | 99.0 | 99.5 | 86.1 | 91.2 |
16 | 이상없음 | 98.8 | 98.9 | 85.2 | 93.8 |
20 | 이상없음 | 97.9 | 98.5 | 85.8 | 93.8 |
24 | 이상없음 | 98.6 | 98.4 | 87.1 | 93.8 |
36 | 이상없음 | 98.7 | 98.5 | 85.1 | 92.8 |
48 | 이상없음 | 98.5 | 98.3 | 86.7 | 91.9 |
P. 팔시파럼 IC50(㎎/㎖) | |||||||||||
3D7 | K1 | VS1 | FCB | Tm90 C2A | FCR3 | ||||||
실험 | 1 | 2 | 1 | 1 | 2 | 1 | 2 | 1 | 2 | 1 | 2 |
알테수네이트 | 3.1 | 4.1 | 1.2 | 1.2 | 2.4 | 2.7 | 3.1 | 3.6 | 3.2 | 2.3 | 2.1 |
디하이드로알테미시닌 | 0.5 | 0.7 | 0.4 | 0.2 | 0.8 | 0.8 | 0.7 | 0.9 | 0.7 | 0.4 | 0.4 |
피로나리딘 | 1.7 | 2.6 | 5.3 | 2.2 | 1.0 | 1.5 | 1.3 | 2.0 | 2.6 | 1.3 | 3.1 |
클로로퀸 | nd | 7.5 | 419 | 446 | 418 | 121 | 74 | 56 | 139 | 206 | 131 |
기생충 | FIC | 고정 약물 비율(피로나리딘:알테수네이트) | |||
4:1 | 3:2 | 2:3 | 1:4 | ||
377 클론 | FIC50 | 1.06 | 1.26 | 2.24 | 1.77 |
FIC90 | 1.07 | 1.22 | 2.11 | 2.13 | |
K1 균주 | FIC50 | 1.19 | 1.4 | 1.59 | 1.22 |
FIC90 | 1.24 | 1.54 | 1.75 | 1.37 | |
VS1 균주 | FIC50 | 1.07 | 0.96 | 1.25 | 1.37 |
FIC90 | 1.03 | 0.93 | 1.04 | 1.42 | |
FCB 균주 | FIC50 | 1.35 | 1.66 | 1.79 | 1.43 |
FIC90 | 1.45 | 1.85 | 1.63 | 1.61 | |
Tm90C2A 균주 | FIC50 | 1.49 | 1.85 | 2.11 | 1.63 |
FIC90 | 1.47 | 2.39 | 2.07 | 1.49 | |
FCR3 균주 | FIC50 | 1.57 | 1.93 | 2.06 | 1.33 |
FIC90 | 2.01 | 2.25 | 2.51 | 1.78 |
말라리아 원충 | ED50(㎎/㎏/일) | ED90(㎎/㎏/일) | I90 |
P. 베르게이 NY | 0.5(0.3-0.9) | 0.8(0.4-1.5) | 1.0 |
P. 베르게이 NPN | 2.0(0.8-5.5) | 0.5(6.5-48.0) | 22.5 |
P. 베르게이 SANA | 0.9(0.6-1.2) | 2.2(1.7-3.2) | 1.2 |
말라리아 원충 | ED50(㎎/㎏/일) | ED90(㎎/㎏/일) | I90 |
P. 베르게이 NY | 6.5(1.8-15.0) | 30.0(8.0-68.0) | 1.0 |
P. 베르게이 NPN | 0.5(0.1-2.0) | 60.0(13.0-260) | 2.0 |
P. 베르게이 SANA | 7.0(2.7-25.0) | 85.0(32.0-300) | 2.8 |
말라리아 원충 | ED50(mg/kg/day) | ED90(mg/kg/day) | I90 |
P. 베르게이 NY | 1.2(0.8-1.4) | 2.0(1.4-2.2) | 1.0 |
P. 베르게이 NPN | 1.8(0.8-3.9) | 11.0(5.0-23.0) | 5.5 |
P. 베르게이 SANA | 1.5(1.3-1.6) | 2.2(1.8-2.5) | 1.1 |
Claims (16)
- 약제학적으로 허용되는 담체와 함께, 유효성분으로서 알테수네이트 및 피로나리딘 또는 그의 염을 포함하되, 상기 알테수네이트가 피로나리딘 또는 그의 염과 직접 접촉되지 않게 조제된 말라리아의 예방 또는 치료를 위한 경구투여용 약제학적 조성물.
- 제1항에 있어서, 알테수네이트와 피로나리딘 또는 그의 염의 중량비가 1:1 내지 1:6인 조성물.
- 제2항에 있어서, 알테수네이트와 피로나리딘 또는 그의 염을 1:3의 중량비로 함유하는 조성물.
- 삭제
- 제1항에 있어서, 알테수네이트가 약제학적으로 허용되는 담체와 함께 마이크로캡슐 또는 과립 형태의 공융 혼합물, 또는 코팅 제제로 제형화된 조성물.
- 제1항에 있어서, 약제학적으로 허용되는 담체가 폴리에틸렌글리콜, 하이드록시프로필 메틸셀룰로스, 메틸셀룰로스 또는 에틸셀룰로스로부터 선택되는 조성물.
- 제6항에 있어서, 약제학적으로 허용되는 담체가 하이드록시프로필 메틸셀룰로스 또는 폴리에틸렌글리콜인 조성물.
- 제7항에 있어서, 알테수네이트와 폴리에틸렌글리콜의 중량비가 1:0.1 내지 1:2인 조성물.
- 삭제
- 제1항에 있어서, 추가로 계면활성제를 포함하는 조성물.
- 삭제
- 제1항에 있어서, 피로나리딘 염은 인산, 황산, 염산, 아세트산, 메탄설폰산, 벤젠설폰산, 톨루엔설폰산, 말레인산 또는 푸마르산과의 산 부가염인 조성물.
- 제12항에 있어서, 피로나리딘 염은 피로나리딘 인산염인 조성물.
- 제1항에 있어서, 정제, 캡슐제, 건조 시럽제 또는 내용 액제 형태의 조성물.
- 알테수네이트를 약제학적으로 허용되는 담체와 함께 1차 제형화한 후, 피로나리딘 또는 그의 염을 혼합하여 최종 제형화하는 단계를 포함하되, 상기 알테수네이트는 상기 피로나리딘 또는 그의 염과 직접 접촉되지 않게 조제된 말라리아의 예방 또는 치료를 위한 경구 투여용 약제학적 조성물을 제조하는 방법.
- 제15항에 있어서, 알테수네이트를 약제학적으로 허용되는 담체와 함께 마이크로캡슐 또는 과립 형태의 공융 혼합물로 제형화하거나, 코팅제로 코팅한 후, 피로나리딘 또는 그의 염을 혼합하여 제형화하는 단계를 포함하는 방법.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040088413A KR100623322B1 (ko) | 2004-11-02 | 2004-11-02 | 경구투여용 항말라리아 배합 제제 및 그의 제조방법 |
AP2005003402A AP2419A (en) | 2004-11-02 | 2005-09-29 | Orally administrable antimalarial combined preparation and preparation process thereof. |
OA1200500281A OA13155A (en) | 2004-11-02 | 2005-10-07 | Orally administrable antmalarial combined preparation and preparation process thereof. |
CN2005800374225A CN101052392B (zh) | 2004-11-02 | 2005-10-14 | 可口服给药的抗疟药组合制剂及其制备方法 |
BRPI0517241A BRPI0517241B8 (pt) | 2004-11-02 | 2005-10-14 | composição farmacêutica, e, método para preparar a mesma |
PCT/KR2005/003432 WO2006049391A1 (en) | 2004-11-02 | 2005-10-14 | Orally administrable antimalarial combined preparation and preparation process thereof |
ZA200703467A ZA200703467B (en) | 2004-11-02 | 2007-04-30 | Orally administrable antimalarial combined preparation and preparation process thereof |
HK08102530.5A HK1113079A1 (en) | 2004-11-02 | 2008-03-05 | Orally administrable antimalarial combined preparation and preparation process thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040088413A KR100623322B1 (ko) | 2004-11-02 | 2004-11-02 | 경구투여용 항말라리아 배합 제제 및 그의 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060039286A KR20060039286A (ko) | 2006-05-08 |
KR100623322B1 true KR100623322B1 (ko) | 2006-09-19 |
Family
ID=36319369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020040088413A KR100623322B1 (ko) | 2004-11-02 | 2004-11-02 | 경구투여용 항말라리아 배합 제제 및 그의 제조방법 |
Country Status (8)
Country | Link |
---|---|
KR (1) | KR100623322B1 (ko) |
CN (1) | CN101052392B (ko) |
AP (1) | AP2419A (ko) |
BR (1) | BRPI0517241B8 (ko) |
HK (1) | HK1113079A1 (ko) |
OA (1) | OA13155A (ko) |
WO (1) | WO2006049391A1 (ko) |
ZA (1) | ZA200703467B (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10792280B2 (en) | 2016-08-12 | 2020-10-06 | Novmetapharma Co., Ltd. | Pharmaceutical composition comprising amodiaquine and anti-diabetes drug as effective ingredient for prevention or treatment of diabetes |
KR20230076573A (ko) | 2021-11-24 | 2023-05-31 | 장은혜 | 야생쑥 추출 천연 아르테미시닌을 함유한 항말라리아용 구강붕해성 필름제제 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101544638B (zh) * | 2009-05-12 | 2012-05-30 | 重庆通天药业有限公司 | 乳酸咯萘啶及其药物组合物 |
EP4129290A4 (en) * | 2020-03-26 | 2023-08-30 | Shin Poong Pharmaceutical Co., Ltd. | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AN EPIDEMIC RNA VIRUS INFECTIOUS DISEASE |
CN113350334A (zh) * | 2021-02-05 | 2021-09-07 | 中国中医科学院中药研究所 | 一种含有双氢青蒿素的抗疟药物 |
WO2022231238A1 (ko) * | 2021-04-26 | 2022-11-03 | 심민보 | 아르테수네이트 또는 그의 염, 및 피로나리딘 또는 그의 염의 해열, 항염증, 항바이러스용, 또는 covid-19 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1200925A (zh) * | 1997-05-30 | 1998-12-09 | 北京市科泰新技术公司 | 一种治疗抗药性恶性疟疾的药物组合物及其制备方法 |
-
2004
- 2004-11-02 KR KR1020040088413A patent/KR100623322B1/ko active IP Right Grant
-
2005
- 2005-09-29 AP AP2005003402A patent/AP2419A/xx active
- 2005-10-07 OA OA1200500281A patent/OA13155A/en unknown
- 2005-10-14 BR BRPI0517241A patent/BRPI0517241B8/pt active IP Right Grant
- 2005-10-14 WO PCT/KR2005/003432 patent/WO2006049391A1/en active Application Filing
- 2005-10-14 CN CN2005800374225A patent/CN101052392B/zh active Active
-
2007
- 2007-04-30 ZA ZA200703467A patent/ZA200703467B/xx unknown
-
2008
- 2008-03-05 HK HK08102530.5A patent/HK1113079A1/xx unknown
Non-Patent Citations (1)
Title |
---|
논문 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10792280B2 (en) | 2016-08-12 | 2020-10-06 | Novmetapharma Co., Ltd. | Pharmaceutical composition comprising amodiaquine and anti-diabetes drug as effective ingredient for prevention or treatment of diabetes |
KR20230076573A (ko) | 2021-11-24 | 2023-05-31 | 장은혜 | 야생쑥 추출 천연 아르테미시닌을 함유한 항말라리아용 구강붕해성 필름제제 |
Also Published As
Publication number | Publication date |
---|---|
WO2006049391A1 (en) | 2006-05-11 |
BRPI0517241B1 (pt) | 2019-10-22 |
BRPI0517241A (pt) | 2008-10-07 |
AP2419A (en) | 2012-06-05 |
HK1113079A1 (en) | 2008-09-26 |
OA13155A (en) | 2006-12-13 |
CN101052392A (zh) | 2007-10-10 |
BRPI0517241B8 (pt) | 2021-05-25 |
KR20060039286A (ko) | 2006-05-08 |
CN101052392B (zh) | 2010-12-15 |
ZA200703467B (en) | 2008-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2562857B2 (ja) | 抗マラリア性組成物 | |
US4537898A (en) | Liquid formulations of dihydropyridines | |
ES2385819T3 (es) | Combinación antirretroviral | |
TWI387456B (zh) | 用於治療瘧疾之二茂鐵氯奎(ferroquine)及黃花蒿素(artemisinin)衍生物之組合 | |
AU2014274890A1 (en) | Pharmaceutical formulations of a HIF hydroxylase inhibitor | |
KR100623322B1 (ko) | 경구투여용 항말라리아 배합 제제 및 그의 제조방법 | |
JP7400180B2 (ja) | 非経口製剤及びその使用 | |
WO2005023304A2 (en) | Antimalarial compositions and manufacturing process thereof | |
WO2007029093A2 (en) | Pharmaceutical dosage forms of oxcarbazepine | |
KR20140053169A (ko) | 아르테롤란 및 피페라퀸의 안정한 제형 | |
CN112020356B (zh) | 作为抗疟疾药物组合的喹啉-4-甲酰胺类和苯并萘啶衍生物的组合 | |
CN113057946A (zh) | 一种双氢青蒿素哌喹片及其制备方法 | |
AU668376B2 (en) | Antimalarial synergistic compositions containing benflumetol | |
WO2007036947A1 (en) | Delayed release anti-malarial composition | |
KR20090073511A (ko) | 플라보노이드 화합물을 유효성분으로 하는 말라리아 치료용약학적 조성물 | |
KR101701547B1 (ko) | 말라리아의 치료 또는 예방에 있어서의 페로퀸의 용도 | |
WO2002026226A1 (fr) | Composition pharmaceutique contenant de la dihydroartemisinine indiquee pour le traitement de la malaria | |
CN102327220B (zh) | 一种氯雷他定脂质体固体制剂 | |
US5637594A (en) | Antimalarial synergistic compositions containing benflumetol | |
CN101953811A (zh) | 一种用于防治老年性痴呆的滴丸组合物及其制备方法 | |
EP0583439B1 (en) | Antimalarial synergistic compositions containing benflumetol | |
CN116898851A (zh) | 一种氧代哒嗪酰胺类衍生物的组合物及其制备方法与医药用途 | |
WO2022090490A1 (en) | Rifaximin liquid formulations for use in the treatment of sickle cell disease | |
CN116898852A (zh) | 一种氧代哒嗪酰胺类衍生物的药物组合物及其制备方法与医药用途 | |
RU2543322C1 (ru) | Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20090831 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20120828 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150907 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160905 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170816 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190829 Year of fee payment: 14 |